Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2023 | The treatment of patients with t(11;14) myeloma

Susan Bal • 10 Jun 2023
EHA 2023
Multiple Myeloma

Susan Bal, MD, MBBS, University of Alabama at Birmingham, Birmingham, AL, comments on the biology and treatment of t(11;14) multiple myeloma, highlighting the efficacy of BCL-2 inhibition and immunotherapy in this subset of patients. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Susan Bal

Updates on the QUINTESSENTIAL trial: second-generation anti-GPRC5D CAR-T in myeloma 0:47
Updates on the QUINTESSENTIAL trial: second-generation anti-GPRC5D CAR-T in myeloma
Susan Bal • 27 Sep 2024
An update on the Phase I trial of BMS-986393, a novel GPRC5D-targeted CAR-T, in R/R myeloma 1:01
An update on the Phase I trial of BMS-986393, a novel GPRC5D-targeted CAR-T, in R/R myeloma
Susan Bal • 27 Sep 2024
Using MRD after autoSCT as a benchmark for consolidation strategies in myeloma 2:03
Using MRD after autoSCT as a benchmark for consolidation strategies in myeloma
Susan Bal • 27 Sep 2024
MILESTONE trial results: MRD response-adapted deferral of autoSCT in newly diagnosed myeloma 2:27
MILESTONE trial results: MRD response-adapted deferral of autoSCT in newly diagnosed myeloma
Susan Bal • 27 Sep 2024

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals